Maxim Group Downgrades NLS Pharmaceutics to Hold
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has downgraded NLS Pharmaceutics (NASDAQ:NLSP) from Buy to Hold.
September 14, 2023 | 11:58 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NLS Pharmaceutics has been downgraded from Buy to Hold by Maxim Group, which could potentially impact the stock's performance.
The downgrade from Buy to Hold by Maxim Group indicates a less optimistic outlook for NLS Pharmaceutics. This could potentially lead to a decrease in the stock's price as investors may interpret this as a signal to sell or avoid buying the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100